<DOC>
	<DOCNO>NCT02137343</DOCNO>
	<brief_summary>This Phase 3 , multicenter , randomize , double-blind , placebo control study Rilotumumab ( AMG 102 ) Cisplatin Capecitabine ( CX ) untreated advanced mesenchymal epithelial transition factor ( MET ) -positive gastric gastroesophageal junction adenocarcinoma ( GEJ ) .</brief_summary>
	<brief_title>A Phase 3 Study Rilotumumab ( AMG 102 ) With Cisplatin Capecitabine ( CX ) First-line Therapy Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key Pathologically confirm unresectable locally advanced metastatic gastric GEJ adenocarcinoma . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 . Tumor METpositive immunohistochemistry ( IHC ) . Measurable disease Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 criterion . Male female subject great equal 20 year age time informed consent . Key Human epidermal growth factor receptor 2 ( HER2 ) overexpressing locally advance metastatic gastric GEJ adenocarcinoma . Previous systemic therapy locally advance metastatic gastric GEJ low esophageal adenocarcinoma . Less 6 month elapse completion prior neoadjuvant adjuvant chemotherapy chemoradiotherapy randomization . Squamous cell histology .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Gastric Cancer</keyword>
	<keyword>First Line Treatment Gastroesophageal Junction ( GEJ )</keyword>
	<keyword>Gastroesophageal Junction Cancer ( GEJ )</keyword>
	<keyword>GEJ Cancer</keyword>
</DOC>